Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RAPT 
RAPT Therapeutics Inc (RAPT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: RAPT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $30
1 Year Target Price $30
| 1 | Strong Buy |
| 1 | Buy |
| 4 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -94.03% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 139.05M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 7 | Beta -0.14 | 52 Weeks Range 5.66 - 30.60 | Updated Date 07/1/2025 |
52 Weeks Range 5.66 - 30.60 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -18.88 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -44.72% | Return on Equity (TTM) -75.6% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -42821599 | Price to Sales(TTM) 411.22 |
Enterprise Value -42821599 | Price to Sales(TTM) 411.22 | ||
Enterprise Value to Revenue 677.37 | Enterprise Value to EBITDA -10.73 | Shares Outstanding 16536100 | Shares Floating 6191111 |
Shares Outstanding 16536100 | Shares Floating 6191111 | ||
Percent Insiders 0.42 | Percent Institutions 99.42 |
Analyst Ratings
Rating 3 | Target Price 30 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 4 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
RAPT Therapeutics Inc
Company Overview
History and Background
RAPT Therapeutics, Inc. (RAPT) was founded in 2015. It is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing, and commercializing oral small molecule therapies for inflammatory diseases and oncology. The company leverages its proprietary discovery and development engine to identify and develop novel drug candidates that selectively target key immune drivers.
Core Business Areas
- Drug Discovery and Development: RAPT focuses on the discovery and development of oral small molecule therapies targeting immune drivers in inflammatory diseases and oncology.
- Clinical Trials: The company conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership and Structure
RAPT Therapeutics is led by Brian Wong, M.D., Ph.D., President and Chief Executive Officer. The company has a management team with experience in drug discovery, development, and commercialization. The organizational structure includes departments focused on research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- FLX475: FLX475 is a CCR4 antagonist being developed for the treatment of cancer. Currently in clinical trials, there is no market share data yet, and it is pre-revenue. Competitors include companies developing other CCR4 antagonists or therapies targeting the same cancer types. Key competitors are companies focused on T cell directed therapies.
- RPT193: RPT193 is an oral small molecule CCR4 antagonist in development for atopic dermatitis (eczema) and asthma. Currently in Phase 1 clinical trials. Market share is not yet applicable as the product is pre-revenue. Competitors include companies with treatments for atopic dermatitis such as Sanofi (SNY) and Regeneron (REGN) with Dupixent.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The immunology market is growing due to the increasing prevalence of inflammatory diseases and cancer.
Positioning
RAPT is positioned as an innovative company developing targeted therapies for inflammatory diseases and oncology using small molecules. Its competitive advantage lies in its proprietary discovery platform and focus on selective immune modulation.
Total Addressable Market (TAM)
The total addressable market for inflammatory disease and oncology therapies is substantial, estimated to be in the hundreds of billions of dollars. RAPT is aiming to capture a portion of this market with its targeted therapies.
Upturn SWOT Analysis
Strengths
- Proprietary drug discovery platform
- Targeted therapies for inflammatory diseases and oncology
- Experienced management team
- Clinical-stage pipeline
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- No approved products
- Relatively small company compared to large pharmaceutical players
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new indications
- Positive clinical trial results
- Regulatory approval and commercialization of products
Threats
- Clinical trial failures
- Competition from other companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- SNY
- REGN
- VRTX
- ABBV
Competitive Landscape
RAPT's advantages include its targeted therapies and proprietary discovery platform. Disadvantages include its limited financial resources and lack of approved products compared to larger pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by progress in clinical trials and expansion of the pipeline.
Future Projections: Future growth is dependent on the successful completion of clinical trials and regulatory approval of its drug candidates. Analyst estimates vary depending on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing FLX475 and RPT193 through clinical trials and exploring new indications for its drug candidates.
Summary
RAPT Therapeutics is a clinical-stage company with a promising pipeline of targeted therapies. Its success depends on the outcomes of ongoing clinical trials and its ability to secure partnerships. The company faces competition and financial challenges typical of biotech firms. Positive clinical data is crucial for future growth and shareholder value. RAPT needs to manage its cash burn and navigate regulatory hurdles effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- RAPT Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise. This analysis is provided for informational purposes only.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About RAPT Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2019-10-31 | CEO, President & Director Dr. Brian Russell Wong M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 67 | Website https://www.rapt.com |
Full time employees 67 | Website https://www.rapt.com | ||
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.